<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Iran Red Crescent Med J</journal-id><journal-id journal-id-type="iso-abbrev">Iran Red Crescent Med J</journal-id><journal-id journal-id-type="doi">10.5812/ircmj</journal-id><journal-id journal-id-type="publisher-id">Kowsar</journal-id><journal-title-group><journal-title>Iranian Red Crescent Medical Journal</journal-title></journal-title-group><issn pub-type="ppub">2074-1804</issn><issn pub-type="epub">2074-1812</issn><publisher><publisher-name>Kowsar</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26566454</article-id><article-id pub-id-type="pmc">4636858</article-id><article-id pub-id-type="doi">10.5812/ircmj.30618</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Evaluating the Role of Corticosteroid Pulse Therapy in Patients With Secondary Progressive Multiple Sclerosis Receiving Mitoxantrone: A Double Blind Randomized Controlled Clinical Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rahimdel</surname><given-names>Abolghasem</given-names></name><xref ref-type="aff" rid="aff72589">1</xref></contrib><contrib contrib-type="author"><name><surname>Zeinali</surname><given-names>Ahmad</given-names></name><xref ref-type="aff" rid="aff72589">1</xref></contrib><contrib contrib-type="author"><name><surname>Mellat</surname><given-names>Ali</given-names></name><xref ref-type="aff" rid="aff72589">1</xref><xref ref-type="corresp" rid="cor72590">*</xref></contrib></contrib-group><aff id="aff72589"><label>1</label>Neurology Department, Shahid Sadoughi Hospital, Shahid Sadoughi University of Medical Sciences, Yazd, IR Iran</aff><author-notes><corresp id="cor72590"><label>*</label>Corresponding Author: Ali Mellat, Neurology Department, Shahid Sadoughi Hospital, Shahid Sadoughi University of Medical Sciences, Yazd, IR Iran. Tel: +98-3538224001, Fax: +98-3538224100, E-mail: <email>Ali_mellat@ssu.ac.ir</email></corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2015</year></pub-date><volume>17</volume><issue>10</issue><elocation-id>e30618</elocation-id><history><date date-type="received"><day>30</day><month>7</month><year>2015</year></date><date date-type="rev-recd"><day>29</day><month>8</month><year>2015</year></date><date date-type="accepted"><day>20</day><month>9</month><year>2015</year></date></history><permissions><copyright-statement>Copyright Â© 2015, Iranian Red Crescent Medical Journal.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p><ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title><offsets xml_i="3368" xml_f="3379" txt_i="11" txt_f="22">Background:</offsets></title><p><offsets xml_i="3390" xml_f="3633" txt_i="23" txt_f="266">Multiple sclerosis (MS) is a central nervous system disorder with periods of recurrence and recovery. Mitoxantrone has been approved for secondary progressive MS (SPMS) treatment but data lacks the role of corticosteroid pulse therapy in SPMS.</offsets></p></sec><sec><title><offsets xml_i="3655" xml_f="3666" txt_i="268" txt_f="279">Objectives:</offsets></title><p><offsets xml_i="3677" xml_f="3775" txt_i="280" txt_f="378">To evaluate the role of corticosteroid pulse therapy in patients with SPMS receiving mitoxantrone.</offsets></p></sec><sec><title><offsets xml_i="3797" xml_f="3818" txt_i="380" txt_f="401">Patients and Methods:</offsets></title><p><offsets xml_i="3829" xml_f="4425" txt_i="402" txt_f="998">A double blind randomized controlled clinical trial was performed on 71 patients with SPMS referred to Shahid Sadoughi Hospital (Yazd, Iran) for receiving mitoxantrone in two groups. The first group (35 patients) received 20 mg mitoxantrone plus 500 mg methylprednisolone monthly for six months. The second group (36 patients) received the same dosage of mitoxantrone plus 100 CC of 5% dextrose water monthly for six months. Expanded disability status scale (EDSS), MRI plaques in both groups before and after the treatment completion and six months after the end of trial were compared together.</offsets></p></sec><sec><title><offsets xml_i="4447" xml_f="4455" txt_i="1000" txt_f="1008">Results:</offsets></title><p><offsets xml_i="4466" xml_f="5053" txt_i="1009" txt_f="1596">28 men and 43 women enrolled in the study. MRI plaques number reduced in groups significantly (2.29 vs. 2.17) without significant difference between the groups (P = 0.782). Six months after trial completion, plaques number increased in groups without significantly difference (0.72 vs. 0.77, P = 0.611). The mean value of EDSS showed significant reduction at the end of treatment in groups (0.79 and 0.53) without significant difference between the groups (P = 0.953). Six months after trial completion, EDSS increased in groups without significant difference (0.35 vs. 0.43, P = 0.624).</offsets></p></sec><sec><title><offsets xml_i="5075" xml_f="5087" txt_i="1598" txt_f="1610">Conclusions:</offsets></title><p><offsets xml_i="5098" xml_f="5364" txt_i="1611" txt_f="1877">Corticosteroid pulse therapy in SPMS was effective in inflammatory process, but could not postpone or decline the neurodegenerative process and besides the imposing side effects could not result in significant improvement in EDSS and MRI plaques number in long term.</offsets></p></sec></abstract><kwd-group kwd-group-type="author"><kwd>Methylprednisolone</kwd><kwd>Mitoxantrone</kwd><kwd>Secondary Progressive Multiple Sclerosis, MS therapy</kwd></kwd-group></article-meta></front><body><sec id="sec128276"><title><offsets xml_i="5603" xml_f="5616" txt_i="1886" txt_f="1899">1. Background</offsets></title><p><offsets xml_i="5627" xml_f="5847" txt_i="1900" txt_f="2120">Multiple sclerosis (MS) is a central nervous system disorder recognized by frequent attacks to optic nerve, spinal cord and brain with periods of recurrence and recovery which could result in disability mainly in youth (</offsets><xref rid="A30618R1" ref-type="bibr"><offsets xml_i="5884" xml_f="5885" txt_i="2120" txt_f="2121">1</offsets></xref><offsets xml_i="5892" xml_f="6070" txt_i="2121" txt_f="2299">). Clinical features are hemiparesis or paraparesis, paresthesia, blurred vision, diplopia, nistagmus, dysarthria, imbalance, deep sensation disturbance and bladder dysfunction (</offsets><xref rid="A30618R2" ref-type="bibr"><offsets xml_i="6107" xml_f="6108" txt_i="2299" txt_f="2300">2</offsets></xref><offsets xml_i="6115" xml_f="6148" txt_i="2300" txt_f="2333">). MS is divided into four types:</offsets></p><list list-type="order" id="L1"><list-item><p><offsets xml_i="6198" xml_f="6284" txt_i="2334" txt_f="2420">Relapse and remitting (RR): periods of relapse with complete recovery or some sequels.</offsets></p></list-item><list-item><p><offsets xml_i="6314" xml_f="6412" txt_i="2421" txt_f="2519">Primary progressive (PP): progression from the beginning with phases of Plato or mild improvement.</offsets></p></list-item><list-item><p><offsets xml_i="6442" xml_f="6534" txt_i="2520" txt_f="2612">Secondary progressive (SP): relapsing and remitting from the beginning and then progression.</offsets></p></list-item><list-item><p><offsets xml_i="6564" xml_f="6676" txt_i="2613" txt_f="2725">Progressive relapsing (PR): progression from the beginning with acute relapses without significant improvement (</offsets><xref rid="A30618R3" ref-type="bibr"><offsets xml_i="6713" xml_f="6714" txt_i="2725" txt_f="2726">3</offsets></xref><offsets xml_i="6721" xml_f="6723" txt_i="2726" txt_f="2728">).</offsets></p></list-item></list><p><offsets xml_i="6749" xml_f="6972" txt_i="2729" txt_f="2952">Most patients with a relapsing-remitting course finally enter a chronic progressive condition (SPMS) with accumulating disability. Progression would continue with or without relapses with minor remissions between relapses (</offsets><xref rid="A30618R4" ref-type="bibr"><offsets xml_i="7009" xml_f="7010" txt_i="2952" txt_f="2953">4</offsets></xref><offsets xml_i="7017" xml_f="7264" txt_i="2953" txt_f="3200">). Sometimes it progresses constantly from the beginning (PPMS), usually occurs in cases with MS after the fourth decade. In progressive relapsing MS, the disease progresses from onset, with clear acute relapses and with or without full recovery (</offsets><xref rid="A30618R2" ref-type="bibr"><offsets xml_i="7301" xml_f="7302" txt_i="3200" txt_f="3201">2</offsets></xref><offsets xml_i="7309" xml_f="7417" txt_i="3201" txt_f="3309">). On the other hand, personal activities and social partnership of the individual are affected by disease (</offsets><xref rid="A30618R5" ref-type="bibr"><offsets xml_i="7454" xml_f="7455" txt_i="3309" txt_f="3310">5</offsets></xref><offsets xml_i="7462" xml_f="7525" txt_i="3310" txt_f="3373">). During the long period, inflammatory infiltrations decline (</offsets><xref rid="A30618R6" ref-type="bibr"><offsets xml_i="7562" xml_f="7563" txt_i="3373" txt_f="3374">6</offsets></xref><offsets xml_i="7570" xml_f="7640" txt_i="3374" txt_f="3444">), while neurodegenerative processes become a more prominent feature (</offsets><xref rid="A30618R7" ref-type="bibr"><offsets xml_i="7677" xml_f="7678" txt_i="3444" txt_f="3445">7</offsets></xref><offsets xml_i="7685" xml_f="8090" txt_i="3445" txt_f="3850">). Recent investigations revealed that inflammatory process in the brain occurs in RRMS and presents in the progressive course. Furthermore, in SPMS, inflammatory process in the meninges could be found. Interestingly, the extent of inflammatory process in the meninges correlates with the amount of neurodegeneration. Therefore, inflammatory process appears to drive tissue degeneration in some patients (</offsets><xref rid="A30618R8" ref-type="bibr"><offsets xml_i="8127" xml_f="8128" txt_i="3850" txt_f="3851">8</offsets></xref><offsets xml_i="8135" xml_f="8315" txt_i="3851" txt_f="4031">). In summary, the inflammatory process is less important during the course of SPMS, while neurodegeneration is the substrate that drives the accumulating neurological disability (</offsets><xref rid="A30618R9" ref-type="bibr"><offsets xml_i="8352" xml_f="8353" txt_i="4031" txt_f="4032">9</offsets></xref><offsets xml_i="8360" xml_f="8511" txt_i="4032" txt_f="4183">). Based on the role of inflammatory and neurodegenerative processes in pathophysiology of SPMS, many drugs have been tested to treat these processes. </offsets><xref ref-type="table" rid="tbl33191"><offsets xml_i="8549" xml_f="8554" txt_i="4183" txt_f="4188">Box 1</offsets></xref><offsets xml_i="8561" xml_f="8652" txt_i="4188" txt_f="4279"> shows approved, not approved but common use and under examination drugs for SPMS therapy (</offsets><xref rid="A30618R9" ref-type="bibr"><offsets xml_i="8689" xml_f="8690" txt_i="4279" txt_f="4280">9</offsets></xref><offsets xml_i="8697" xml_f="8699" txt_i="4280" txt_f="4282">).</offsets></p><table-wrap id="tbl33191" orientation="portrait" position="float"><label><offsets xml_i="8776" xml_f="8782" txt_i="4283" txt_f="4289">Box 1.</offsets></label><caption><title><offsets xml_i="8806" xml_f="8868" txt_i="4289" txt_f="4351"> Therapies for Secondary Progressive Multiple Sclerosis (SPMS)</offsets></title></caption><table frame="hsides" rules="groups"><thead><tr><th style="text-align: left;" rowspan="1" colspan="1"><offsets xml_i="8988" xml_f="8996" txt_i="4352" txt_f="4360">Approved</offsets></th></tr></thead><tbody><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1"><offsets xml_i="9081" xml_f="9099" txt_i="4360" txt_f="4378">Interferon Beta 1b</offsets></td></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1"><offsets xml_i="9169" xml_f="9187" txt_i="4379" txt_f="4397">Interferon Beta 1a</offsets></td></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1"><offsets xml_i="9257" xml_f="9269" txt_i="4398" txt_f="4410">Mitoxantrone</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="9311" xml_f="9312" txt_i="4411" txt_f="4412">
</offsets><bold><offsets xml_i="9318" xml_f="9341" txt_i="4412" txt_f="4435">Not approved but common</offsets></bold><offsets xml_i="9348" xml_f="9349" txt_i="4435" txt_f="4436">
</offsets></td></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1"><offsets xml_i="9419" xml_f="9445" txt_i="4437" txt_f="4463">Intravenous Immunoglobulin</offsets></td></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1"><offsets xml_i="9515" xml_f="9530" txt_i="4464" txt_f="4479">Corticosteroids</offsets></td></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1"><offsets xml_i="9600" xml_f="9612" txt_i="4480" txt_f="4492">Azathioprine</offsets></td></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1"><offsets xml_i="9682" xml_f="9698" txt_i="4493" txt_f="4509">Cyclophosphamide</offsets></td></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1"><offsets xml_i="9768" xml_f="9781" txt_i="4510" txt_f="4523">Mycophenolate</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="9823" xml_f="9824" txt_i="4524" txt_f="4525">
</offsets><bold><offsets xml_i="9830" xml_f="9847" txt_i="4525" txt_f="4542">Under examination</offsets></bold><offsets xml_i="9854" xml_f="9855" txt_i="4542" txt_f="4543">
</offsets></td></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1"><offsets xml_i="9925" xml_f="9935" txt_i="4544" txt_f="4554">Daclizumab</offsets></td></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1"><offsets xml_i="10005" xml_f="10014" txt_i="4555" txt_f="4564">Rituximab</offsets></td></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1"><offsets xml_i="10084" xml_f="10123" txt_i="4565" txt_f="4604">Hematopoietic stem cell transplantation</offsets></td></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1"><offsets xml_i="10193" xml_f="10202" txt_i="4605" txt_f="4614">Masitinib</offsets></td></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1"><offsets xml_i="10272" xml_f="10282" txt_i="4615" txt_f="4625">Fingolimod</offsets></td></tr></tbody></table></table-wrap><p><offsets xml_i="10324" xml_f="10424" txt_i="4626" txt_f="4726">Mitoxantrone (drug for breast cancer chemotherapy) has been approved for SPMS treatment since 2002 (</offsets><xref rid="A30618R10" ref-type="bibr"><offsets xml_i="10462" xml_f="10464" txt_i="4726" txt_f="4728">10</offsets></xref><offsets xml_i="10471" xml_f="10632" txt_i="4728" txt_f="4889">). Mild adverse effects are transient leukopenia, liver enzymes elevation, nausea, vomiting, transient alopecia, urine color change and urinary tract infection (</offsets><xref rid="A30618R11" ref-type="bibr"><offsets xml_i="10670" xml_f="10672" txt_i="4889" txt_f="4891">11</offsets></xref><offsets xml_i="10679" xml_f="10808" txt_i="4891" txt_f="5020">). Moreover, mitoxantrone has serious but uncommon adverse effects such as bone marrow suppression, acute leukemia, infertility (</offsets><xref rid="A30618R12" ref-type="bibr"><offsets xml_i="10846" xml_f="10848" txt_i="5020" txt_f="5022">12</offsets></xref><offsets xml_i="10855" xml_f="10909" txt_i="5022" txt_f="5076">) and cardio toxicity with cumulative dose of 140 mg/m</offsets><sup><offsets xml_i="10914" xml_f="10915" txt_i="5076" txt_f="5077">2</offsets></sup><offsets xml_i="10921" xml_f="10923" txt_i="5077" txt_f="5079"> (</offsets><xref rid="A30618R13" ref-type="bibr"><offsets xml_i="10961" xml_f="10963" txt_i="5079" txt_f="5081">13</offsets></xref><offsets xml_i="10970" xml_f="11007" txt_i="5081" txt_f="5118">). It could be prescribed 5 - 12 mg/m</offsets><sup><offsets xml_i="11012" xml_f="11013" txt_i="5118" txt_f="5119">2</offsets></sup><offsets xml_i="11019" xml_f="11065" txt_i="5119" txt_f="5165"> intravenously monthly or every three months (</offsets><xref rid="A30618R14" ref-type="bibr"><offsets xml_i="11103" xml_f="11105" txt_i="5165" txt_f="5167">14</offsets></xref><offsets xml_i="11112" xml_f="11267" txt_i="5167" txt_f="5322">). The probable effects of mitoxantrone are relapse reduction, expanded disability status scale (EDSS) improvement and slowing the disability progression (</offsets><xref rid="A30618R15" ref-type="bibr"><offsets xml_i="11305" xml_f="11307" txt_i="5322" txt_f="5324">15</offsets></xref><offsets xml_i="11314" xml_f="11521" txt_i="5324" txt_f="5531">). On the other hand, methylprednisolone has been used for progressive MS. Standard therapy for acute relapse of MS is pulse therapy with high dose of methylprednisolone 500 - 1000 mg/daily for 3 to 5 days (</offsets><xref rid="A30618R16" ref-type="bibr"><offsets xml_i="11559" xml_f="11561" txt_i="5531" txt_f="5533">16</offsets></xref><offsets xml_i="11568" xml_f="11660" txt_i="5533" txt_f="5625">). New evidences show that severity of clinical signs and symptoms reduce by this protocol (</offsets><xref rid="A30618R17" ref-type="bibr"><offsets xml_i="11698" xml_f="11700" txt_i="5625" txt_f="5627">17</offsets></xref><offsets xml_i="11707" xml_f="12048" txt_i="5627" txt_f="5968">). As treatment protocols in SPMS are still limited, corticosteroids are used in SPMS. Although its efficacy in SPMS is not proven, the role of corticosteroids in treatment of progressive MS is still obscured. Different studies showed that corticosteroids may improve inflammation, but at later stages degeneration can hardly be influenced (</offsets><xref rid="A30618R17" ref-type="bibr"><offsets xml_i="12086" xml_f="12088" txt_i="5968" txt_f="5970">17</offsets></xref><offsets xml_i="12095" xml_f="12096" txt_i="5970" txt_f="5971">-</offsets><xref rid="A30618R20" ref-type="bibr"><offsets xml_i="12134" xml_f="12136" txt_i="5971" txt_f="5973">20</offsets></xref><offsets xml_i="12143" xml_f="12413" txt_i="5973" txt_f="6243">). First dose of intravenous methylprednisolone is usually administered in hospital for safety reasons. Potentially severe adverse effects are epileptic seizures, psychotic reactions, cognitive decline, venous thrombosis, anaphylactic reactions and cardiac arrhythmias (</offsets><xref rid="A30618R21" ref-type="bibr"><offsets xml_i="12451" xml_f="12453" txt_i="6243" txt_f="6245">21</offsets></xref><offsets xml_i="12460" xml_f="12461" txt_i="6245" txt_f="6246">-</offsets><xref rid="A30618R25" ref-type="bibr"><offsets xml_i="12499" xml_f="12501" txt_i="6246" txt_f="6248">25</offsets></xref><offsets xml_i="12508" xml_f="12681" txt_i="6248" txt_f="6421">). Furthermore, one study suggested that co-administration of mitoxantrone and methylprednisolone may reduce the progression of disability in patients with PP-MS and SP-MS (</offsets><xref rid="A30618R26" ref-type="bibr"><offsets xml_i="12719" xml_f="12721" txt_i="6421" txt_f="6423">26</offsets></xref><offsets xml_i="12728" xml_f="12730" txt_i="6423" txt_f="6425">).</offsets></p></sec><sec id="sec128280"><title><offsets xml_i="12767" xml_f="12780" txt_i="6427" txt_f="6440">2. Objectives</offsets></title><p><offsets xml_i="12791" xml_f="12977" txt_i="6441" txt_f="6627">The purpose of the present study was to evaluate the role corticosteroid pulse therapy in patients with SPMS referred to Shahid Sadoughi Hospital (Yazd, Iran) for receiving mitoxantrone.</offsets></p></sec><sec id="sec128277"><title><offsets xml_i="13014" xml_f="13037" txt_i="6629" txt_f="6652">3. Patients and Methods</offsets></title><p><offsets xml_i="13048" xml_f="13394" txt_i="6653" txt_f="6999">Our study was a double blind randomized clinical trial performed in Shahid Sadoughi Hospital (Referral, Specialized, Governmental, 576 beds and 22 sections) of Yazd, Iran on 82 patients (aged 20 to 50 years) with SPMS referred for receiving mitoxantrone [(trial code: IRCT201107145943N3), IRCT: Iran registry of clinical trials]. The sample size </offsets><xref ref-type="disp-formula" rid="EQ3924"><offsets xml_i="13437" xml_f="13444" txt_i="6999" txt_f="7006">formula</offsets></xref><offsets xml_i="13451" xml_f="13456" txt_i="7006" txt_f="7011"> was:</offsets></p><disp-formula id="EQ3924"><label><offsets xml_i="13493" xml_f="13497" txt_i="7012" txt_f="7016">(1).</offsets></label><mml:math id="MML3924"><mml:mstyle displaystyle="true"><mml:mrow><mml:mi><offsets xml_i="13578" xml_f="13580" txt_i="7016" txt_f="7018">x </offsets></mml:mi><mml:mo><offsets xml_i="13597" xml_f="13598" txt_i="7018" txt_f="7019">=</offsets></mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false"><offsets xml_i="13652" xml_f="13653" txt_i="7019" txt_f="7020">(</offsets></mml:mo><mml:msub><mml:mrow><mml:mi><offsets xml_i="13690" xml_f="13691" txt_i="7020" txt_f="7021">z</offsets></mml:mi></mml:mrow><mml:mrow><mml:mn><offsets xml_i="13729" xml_f="13730" txt_i="7021" txt_f="7022">1</offsets></mml:mn><mml:mtext><offsets xml_i="13750" xml_f="13751" txt_i="7022" txt_f="7023">
</offsets></mml:mtext><mml:mo><offsets xml_i="13771" xml_f="13772" txt_i="7023" txt_f="7024">-</offsets></mml:mo><mml:mfrac><mml:mrow><mml:mi><offsets xml_i="13810" xml_f="13811" txt_i="7024" txt_f="7025">Î±</offsets></mml:mi></mml:mrow><mml:mrow><mml:mn><offsets xml_i="13849" xml_f="13850" txt_i="7025" txt_f="7026">2</offsets></mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:msub><mml:mo><offsets xml_i="13912" xml_f="13913" txt_i="7026" txt_f="7027">+</offsets></mml:mo><mml:msub><mml:mrow><mml:mi><offsets xml_i="13950" xml_f="13951" txt_i="7027" txt_f="7028">z</offsets></mml:mi></mml:mrow><mml:mrow><mml:mn><offsets xml_i="13989" xml_f="13990" txt_i="7028" txt_f="7029">1</offsets></mml:mn><mml:mtext><offsets xml_i="14010" xml_f="14011" txt_i="7029" txt_f="7030">
</offsets></mml:mtext><mml:mo><offsets xml_i="14031" xml_f="14032" txt_i="7030" txt_f="7031">-</offsets></mml:mo><mml:mi><offsets xml_i="14049" xml_f="14051" txt_i="7031" txt_f="7033"> Î²</offsets></mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false"><offsets xml_i="14107" xml_f="14108" txt_i="7033" txt_f="7034">)</offsets></mml:mo></mml:mrow><mml:mrow><mml:mn><offsets xml_i="14146" xml_f="14147" txt_i="7034" txt_f="7035">2</offsets></mml:mn></mml:mrow></mml:msup><mml:mo><offsets xml_i="14186" xml_f="14187" txt_i="7035" txt_f="7036">Ã</offsets></mml:mo><mml:mfrac><mml:mrow><mml:mn><offsets xml_i="14225" xml_f="14226" txt_i="7036" txt_f="7037">2</offsets></mml:mn><mml:msup><mml:mrow><mml:mi><offsets xml_i="14263" xml_f="14264" txt_i="7037" txt_f="7038">S</offsets></mml:mi></mml:mrow><mml:mrow><mml:mn><offsets xml_i="14302" xml_f="14303" txt_i="7038" txt_f="7039">2</offsets></mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi><offsets xml_i="14383" xml_f="14384" txt_i="7039" txt_f="7040">d</offsets></mml:mi></mml:mrow><mml:mrow><mml:mn><offsets xml_i="14422" xml_f="14423" txt_i="7040" txt_f="7041">2</offsets></mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></disp-formula><p><offsets xml_i="14530" xml_f="14550" txt_i="7041" txt_f="7061">(S = 4 and d = 2.5).</offsets></p><p><offsets xml_i="14557" xml_f="14790" txt_i="7062" txt_f="7295">The expected power was 80%. Normal assumption and repeated measurement assumption were checked precisely. Simple randomized sampling procedure was performed based on the study criteria using the âRandom Allocation Softwareâ program (</offsets><xref ref-type="fig" rid="fig24425"><offsets xml_i="14826" xml_f="14834" txt_i="7295" txt_f="7303">Figure 1</offsets></xref><offsets xml_i="14841" xml_f="17387" txt_i="7303" txt_f="9849">). Eleven patients withdrew the trial due to refractory vomiting (4 patients), urinary tract or gastrointestinal infection (3 patients) and unreliability to the treatment results (4 patients). Inclusion criteria were any patient with SPMS between 20 - 50 years old, progressive deterioration period of at least 6 months and less than 4 years, EDSS between 4.0 and 7. Exclusion criteria were immune deficiency, cancer, pregnancy, breast feeding, renal or heart failure, diabetes mellitus and tuberculosis. Patients with leukopenia during the injection (neutrophils less than 1500/mL) and those who had received corticosteroids within 6 months before the trial were excluded from the trial. Finally, 71 patients enrolled in the study and randomly assigned into two groups. The first group (35 patients) received 20 mg mitoxantrone plus 500 mg methylprednisolone intravenously and the other group (36 patients) received the same dose of mitoxantrone and 100 CC of 5% dextrose water monthly for consecutive six months. All patients were evaluated by neurological exam, especially expanded disability status scale (EDSS), MRI of the brain and spinal cord (1.5 Tesla, without contrast, T2 phase), cell blood count, hepatic tests and echocardiography before the treatment establishment. At the end of drug administration completion (sixth month), they were evaluated again by EDSS, MRI, blood cell count, hepatic tests and echocardiography. At the twelfth month they were evaluated repeatedly by EDSS and MRI plaque number. The patients, nurses administering the drugs and those registering the signs and symptoms of the patients were blinded to the study design. Neurologic examinations before and after the treatment were performed by one neurologist who was unaware of the treatment methods. Furthermore, by MRI study (1.5 Tesla, without contrast), the number of plaques in the brain and spinal cord were measured by a radiologist unaware of the type of treatments. At the sixth month, the above mentioned checkups were performed (by the same neurologist) and the number of plaques were measured (by the same radiologist) and compared to those before the trial establishment. Six months after the study completion, EDSS and MRI plaques were measured again. An informed consent was obtained from all patients. The ethics committee of Yazd University of Medical Sciences approved the study. Finally, gathered data was analyzed using statistical tests of t-test, chi-square, paired sample t-test and repeated measure ANOVA by SPSS version 11.5 software.</offsets></p><fig id="fig24425" orientation="portrait" position="float"><label><offsets xml_i="17457" xml_f="17466" txt_i="9850" txt_f="9859">Figure 1.</offsets></label><caption><title><offsets xml_i="17490" xml_f="17510" txt_i="9859" txt_f="9879">CONSORT Flow Diagram</offsets></title></caption><graphic xlink:href="ircmj-17-10-30618-i001"></graphic></fig></sec><sec id="sec128278"><title><offsets xml_i="17622" xml_f="17632" txt_i="9881" txt_f="9891">4. Results</offsets></title><p><offsets xml_i="17643" xml_f="17869" txt_i="9892" txt_f="10115">Of 71 patients who completed the study, 28 patients were males (39.4%) and 43 females (60.6%). Age, sex and disease duration were not different significantly between the groups (P &gt; 0.05). Demographic features are shown in </offsets><xref ref-type="table" rid="tbl33192"><offsets xml_i="17907" xml_f="17914" txt_i="10115" txt_f="10122">Table 1</offsets></xref><offsets xml_i="17921" xml_f="18456" txt_i="10122" txt_f="10654">. The main index evaluated in this study was the number of plaques in MRI of patients in the both groups before and after the treatment (sixth month and twelfth month). The mean number of MRI plaques showed significant reduction in the both groups after the treatment (P value &lt; 0.05), but difference between the groups was not significant (P value = 0.782). Although the number of plaques increased in the both groups during 6 months after trial completion, the difference was not significant between the groups (P value = 0.611) (</offsets><xref ref-type="table" rid="tbl33193"><offsets xml_i="18494" xml_f="18501" txt_i="10654" txt_f="10661">Table 2</offsets></xref><offsets xml_i="18508" xml_f="18829" txt_i="10661" txt_f="10979">). EDSS reduced significantly in the both groups at the end of treatment completion (P value &lt; 0.05), but the difference between the groups was not significant (P value = 0.953). During six months after treatment completion, EDSS increased in the both groups, but the difference was not significant (P value = 0.624) (</offsets><xref ref-type="table" rid="tbl33194"><offsets xml_i="18867" xml_f="18874" txt_i="10979" txt_f="10986">Table 3</offsets></xref><offsets xml_i="18881" xml_f="18883" txt_i="10986" txt_f="10988">).</offsets></p><table-wrap id="tbl33192" orientation="portrait" position="float"><label><offsets xml_i="18960" xml_f="18968" txt_i="10989" txt_f="10997">Table 1.</offsets></label><caption><title><offsets xml_i="18992" xml_f="19027" txt_i="10997" txt_f="11032"> Demographic Features of the Groups</offsets></title></caption><table frame="hsides" rules="groups"><thead><tr><th style="text-align: left;vertical-align: top;" rowspan="2" colspan="1"><offsets xml_i="19167" xml_f="19177" txt_i="11033" txt_f="11043">Variations</offsets></th><th style="border-bottom: solid thin;" colspan="2" rowspan="1"><offsets xml_i="19245" xml_f="19251" txt_i="11043" txt_f="11049">Groups</offsets></th><th style="vertical-align: top;" rowspan="2" colspan="1"><offsets xml_i="19313" xml_f="19320" txt_i="11049" txt_f="11056">P Value</offsets></th></tr><tr><th rowspan="1" colspan="1"><offsets xml_i="19362" xml_f="19379" txt_i="11056" txt_f="11073">Mitoxantrone + MP</offsets></th><th rowspan="1" colspan="1"><offsets xml_i="19412" xml_f="19424" txt_i="11073" txt_f="11085">Mitoxantrone</offsets></th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><offsets xml_i="19481" xml_f="19482" txt_i="11085" txt_f="11086">
</offsets><bold><offsets xml_i="19488" xml_f="19492" txt_i="11086" txt_f="11090">Age </offsets></bold><offsets xml_i="19499" xml_f="19500" txt_i="11090" txt_f="11091">
</offsets><sup><bold><xref ref-type="table-fn" rid="fn34791"><offsets xml_i="19551" xml_f="19552" txt_i="11091" txt_f="11092">a</offsets></xref></bold></sup><offsets xml_i="19572" xml_f="19573" txt_i="11092" txt_f="11093">
</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="19634" xml_f="19644" txt_i="11094" txt_f="11104">36.5 Â± 9.2</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="19705" xml_f="19716" txt_i="11105" txt_f="11116">35.7 Â± 10.6</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="19777" xml_f="19782" txt_i="11117" txt_f="11122">0.735</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="19824" xml_f="19825" txt_i="11123" txt_f="11124">
</offsets><bold><offsets xml_i="19831" xml_f="19842" txt_i="11124" txt_f="11135">Male/Female</offsets></bold><offsets xml_i="19849" xml_f="19850" txt_i="11135" txt_f="11136">
</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="19911" xml_f="19914" txt_i="11137" txt_f="11140">3/4</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="19975" xml_f="19978" txt_i="11141" txt_f="11144">4/5</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="20039" xml_f="20040" txt_i="11145" txt_f="11146">1</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="20082" xml_f="20083" txt_i="11147" txt_f="11148">
</offsets><bold><offsets xml_i="20089" xml_f="20110" txt_i="11148" txt_f="11169">Disease duration, mo </offsets></bold><offsets xml_i="20117" xml_f="20118" txt_i="11169" txt_f="11170">
</offsets><sup><bold><xref ref-type="table-fn" rid="fn34791"><offsets xml_i="20169" xml_f="20170" txt_i="11170" txt_f="11171">a</offsets></xref></bold></sup><offsets xml_i="20190" xml_f="20191" txt_i="11171" txt_f="11172">
</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="20252" xml_f="20263" txt_i="11173" txt_f="11184">69.1 Â± 45.6</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="20324" xml_f="20335" txt_i="11185" txt_f="11196">74.8 Â± 42.2</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="20396" xml_f="20401" txt_i="11197" txt_f="11202">0.587</offsets></td></tr></tbody></table><table-wrap-foot><fn id="fn34791"><p><sup><offsets xml_i="20469" xml_f="20470" txt_i="11203" txt_f="11204">a</offsets></sup><offsets xml_i="20476" xml_f="20509" txt_i="11204" txt_f="11237">Values are presented as meanÂ± SD.</offsets></p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl33193" orientation="portrait" position="float"><label><offsets xml_i="20622" xml_f="20630" txt_i="11238" txt_f="11246">Table 2.</offsets></label><caption><title><offsets xml_i="20654" xml_f="20695" txt_i="11246" txt_f="11287"> Comparing MRI Plaques Between the Groups</offsets><sup><xref ref-type="table-fn" rid="fn34792"><offsets xml_i="20740" xml_f="20741" txt_i="11287" txt_f="11288">a</offsets></xref><offsets xml_i="20748" xml_f="20749" txt_i="11288" txt_f="11289">,</offsets><xref ref-type="table-fn" rid="fn34793"><offsets xml_i="20789" xml_f="20790" txt_i="11289" txt_f="11290">b</offsets></xref></sup></title></caption><table frame="hsides" rules="groups"><thead><tr><th style="text-align: left;vertical-align: top;" rowspan="2" colspan="1"><offsets xml_i="20943" xml_f="20949" txt_i="11291" txt_f="11297">Groups</offsets></th><th style="border-bottom: solid thin;" colspan="3" rowspan="1"><offsets xml_i="21017" xml_f="21036" txt_i="11297" txt_f="11316">MRI Plaques Number </offsets><sup><xref ref-type="table-fn" rid="fn34794"><offsets xml_i="21081" xml_f="21082" txt_i="11316" txt_f="11317">c</offsets></xref></sup></th></tr><tr><th style="vertical-align: top;" rowspan="1" colspan="1"><offsets xml_i="21166" xml_f="21186" txt_i="11317" txt_f="11337">Before the Treatment</offsets></th><th style="vertical-align: top;" rowspan="1" colspan="1"><offsets xml_i="21248" xml_f="21268" txt_i="11337" txt_f="11357">End of the Treatment</offsets></th><th style="vertical-align: top;" rowspan="1" colspan="1"><offsets xml_i="21330" xml_f="21365" txt_i="11357" txt_f="11392">6 Months After Treatment Completion</offsets></th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><offsets xml_i="21422" xml_f="21423" txt_i="11392" txt_f="11393">
</offsets><bold><offsets xml_i="21429" xml_f="21446" txt_i="11393" txt_f="11410">Mitoxantrone + MP</offsets></bold><offsets xml_i="21453" xml_f="21454" txt_i="11410" txt_f="11411">
</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="21515" xml_f="21526" txt_i="11412" txt_f="11423">10.6 Â± 4.37</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="21587" xml_f="21598" txt_i="11424" txt_f="11435">8.31 Â± 4.06</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="21659" xml_f="21670" txt_i="11436" txt_f="11447">9.03 Â± 3.56</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="21712" xml_f="21713" txt_i="11448" txt_f="11449">
</offsets><bold><offsets xml_i="21719" xml_f="21731" txt_i="11449" txt_f="11461">Mitoxantrone</offsets></bold><offsets xml_i="21738" xml_f="21739" txt_i="11461" txt_f="11462">
</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="21800" xml_f="21811" txt_i="11463" txt_f="11474">10.8 Â± 4.56</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="21872" xml_f="21883" txt_i="11475" txt_f="11486">8.63 Â± 3.95</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="21944" xml_f="21954" txt_i="11487" txt_f="11497">9.4 Â± 4.33</offsets></td></tr></tbody></table><table-wrap-foot><fn id="fn34792"><p><sup><offsets xml_i="22022" xml_f="22023" txt_i="11498" txt_f="11499">a</offsets></sup><offsets xml_i="22029" xml_f="22087" txt_i="11499" txt_f="11557">P value between before and the end of treatment was 0.782.</offsets></p></fn><fn id="fn34793"><p><sup><offsets xml_i="22121" xml_f="22122" txt_i="11558" txt_f="11559">b</offsets></sup><offsets xml_i="22128" xml_f="22221" txt_i="11559" txt_f="11652">P value between before the treatment and six months after the treatment completion was 0.611.</offsets></p></fn><fn id="fn34794"><p><sup><offsets xml_i="22255" xml_f="22256" txt_i="11653" txt_f="11654">c</offsets></sup><offsets xml_i="22262" xml_f="22296" txt_i="11654" txt_f="11688">values are presented as mean Â± SD.</offsets></p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl33194" orientation="portrait" position="float"><label><offsets xml_i="22409" xml_f="22417" txt_i="11689" txt_f="11697">Table 3.</offsets></label><caption><title><offsets xml_i="22441" xml_f="22473" txt_i="11697" txt_f="11729"> EDSS of Groups During the Study</offsets><sup><xref ref-type="table-fn" rid="fn34795"><offsets xml_i="22518" xml_f="22519" txt_i="11729" txt_f="11730">a</offsets></xref><offsets xml_i="22526" xml_f="22527" txt_i="11730" txt_f="11731">,</offsets><xref ref-type="table-fn" rid="fn34796"><offsets xml_i="22567" xml_f="22568" txt_i="11731" txt_f="11732">b</offsets></xref></sup></title></caption><table frame="hsides" rules="groups"><thead><tr><th style="text-align: left;vertical-align: top;" rowspan="2" colspan="1"><offsets xml_i="22721" xml_f="22727" txt_i="11733" txt_f="11739">Groups</offsets></th><th style="border-bottom: solid thin;" colspan="3" rowspan="1"><offsets xml_i="22795" xml_f="22800" txt_i="11739" txt_f="11744">EDSS </offsets><sup><xref ref-type="table-fn" rid="fn34797"><offsets xml_i="22845" xml_f="22846" txt_i="11744" txt_f="11745">c</offsets></xref></sup></th></tr><tr><th style="vertical-align: top;" rowspan="1" colspan="1"><offsets xml_i="22930" xml_f="22950" txt_i="11745" txt_f="11765">Before the Treatment</offsets></th><th style="vertical-align: top;" rowspan="1" colspan="1"><offsets xml_i="23012" xml_f="23032" txt_i="11765" txt_f="11785">End of the Treatment</offsets></th><th style="vertical-align: top;" rowspan="1" colspan="1"><offsets xml_i="23094" xml_f="23133" txt_i="11785" txt_f="11824">6 Months After the Treatment Completion</offsets></th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><offsets xml_i="23190" xml_f="23191" txt_i="11824" txt_f="11825">
</offsets><bold><offsets xml_i="23197" xml_f="23214" txt_i="11825" txt_f="11842">Mitoxantrone + MP</offsets></bold><offsets xml_i="23221" xml_f="23222" txt_i="11842" txt_f="11843">
</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="23283" xml_f="23294" txt_i="11844" txt_f="11855">5.40 Â± 1.46</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="23355" xml_f="23366" txt_i="11856" txt_f="11867">4.61 Â± 1.87</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="23427" xml_f="23438" txt_i="11868" txt_f="11879">4.96 Â± 1.63</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="23480" xml_f="23481" txt_i="11880" txt_f="11881">
</offsets><bold><offsets xml_i="23487" xml_f="23499" txt_i="11881" txt_f="11893">Mitoxantrone</offsets></bold><offsets xml_i="23506" xml_f="23507" txt_i="11893" txt_f="11894">
</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="23568" xml_f="23579" txt_i="11895" txt_f="11906">5.17 Â± 2.10</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="23640" xml_f="23651" txt_i="11907" txt_f="11918">4.64 Â± 2.16</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="23712" xml_f="23723" txt_i="11919" txt_f="11930">5.07 Â± 1.92</offsets></td></tr></tbody></table><table-wrap-foot><fn id="fn34795"><p><sup><offsets xml_i="23791" xml_f="23792" txt_i="11931" txt_f="11932">a</offsets></sup><offsets xml_i="23798" xml_f="23904" txt_i="11932" txt_f="12038">P value comparing EDSS changes before the treatment and end of the treatment between the groups was 0.953.</offsets></p></fn><fn id="fn34796"><p><sup><offsets xml_i="23938" xml_f="23939" txt_i="12039" txt_f="12040">b</offsets></sup><offsets xml_i="23945" xml_f="24051" txt_i="12040" txt_f="12146">P value comparing EDSS changes before the treatment and end of the treatment between the groups was 0.624.</offsets></p></fn><fn id="fn34797"><p><sup><offsets xml_i="24085" xml_f="24086" txt_i="12147" txt_f="12148">c</offsets></sup><offsets xml_i="24092" xml_f="24126" txt_i="12148" txt_f="12182">values are presented as mean Â± SD.</offsets></p></fn></table-wrap-foot></table-wrap></sec><sec id="sec128279"><title><offsets xml_i="24199" xml_f="24212" txt_i="12184" txt_f="12197">5. Discussion</offsets></title><p><offsets xml_i="24223" xml_f="24551" txt_i="12198" txt_f="12523">In our trial, age, sex and duration of disease were not different statistically between the groups (P &gt; 0.05). Today, the use of MRI makes it easier to evaluate patients with MS, in a way that it is possible to assess the activity of disease without clinical symptoms; furthermore, it can be used as a measurement criterion (</offsets><xref rid="A30618R27" ref-type="bibr"><offsets xml_i="24589" xml_f="24591" txt_i="12523" txt_f="12525">27</offsets></xref><offsets xml_i="24598" xml_f="24600" txt_i="12525" txt_f="12527">, </offsets><xref rid="A30618R28" ref-type="bibr"><offsets xml_i="24638" xml_f="24640" txt_i="12527" txt_f="12529">28</offsets></xref><offsets xml_i="24647" xml_f="24936" txt_i="12529" txt_f="12818">). However due to limited facilities of our trial, the use of gadolinium contrast and obtaining MRI serially were not possible. Previous studies showed that mitoxantrone decreased the number of plaques in secondary progressive MS from 52% to 89% compared to placebo or methylprednisolone (</offsets><xref rid="A30618R15" ref-type="bibr"><offsets xml_i="24974" xml_f="24976" txt_i="12818" txt_f="12820">15</offsets></xref><offsets xml_i="24983" xml_f="24985" txt_i="12820" txt_f="12822">, </offsets><xref rid="A30618R29" ref-type="bibr"><offsets xml_i="25023" xml_f="25025" txt_i="12822" txt_f="12824">29</offsets></xref><offsets xml_i="25032" xml_f="25033" txt_i="12824" txt_f="12825">-</offsets><xref rid="A30618R31" ref-type="bibr"><offsets xml_i="25071" xml_f="25073" txt_i="12825" txt_f="12827">31</offsets></xref><offsets xml_i="25080" xml_f="25699" txt_i="12827" txt_f="13440">). Our study showed that MS plaques decreased in both groups significantly (P &lt; 0.05), but there was no difference between the groups (P &gt; 0.05), so adding methylprednisolone to mitoxantrone had no significant influence on the number of plaques reduction. The number of plaques increased in both groups during six months after trial completion, but the difference between groups was not significant. It means that adding methylprednisolone to mitoxantrone had no influence on MRI plaques significantly. Numerous studies implicated the efficacy of mitoxantrone on declining EDSS or slowing disability progression (</offsets><xref rid="A30618R15" ref-type="bibr"><offsets xml_i="25737" xml_f="25739" txt_i="13440" txt_f="13442">15</offsets></xref><offsets xml_i="25746" xml_f="25748" txt_i="13442" txt_f="13444">, </offsets><xref rid="A30618R30" ref-type="bibr"><offsets xml_i="25786" xml_f="25788" txt_i="13444" txt_f="13446">30</offsets></xref><offsets xml_i="25795" xml_f="25797" txt_i="13446" txt_f="13448">, </offsets><xref rid="A30618R32" ref-type="bibr"><offsets xml_i="25835" xml_f="25837" txt_i="13448" txt_f="13450">32</offsets></xref><offsets xml_i="25844" xml_f="25952" txt_i="13450" txt_f="13558">). Also studies comparing the efficacy of mitoxantrone plus methylprednisolone to methylprednisolone alone (</offsets><xref rid="A30618R29" ref-type="bibr"><offsets xml_i="25990" xml_f="25992" txt_i="13558" txt_f="13560">29</offsets></xref><offsets xml_i="25999" xml_f="26049" txt_i="13560" txt_f="13610">) or mitoxantrone compared to methylprednisolone (</offsets><xref rid="A30618R33" ref-type="bibr"><offsets xml_i="26087" xml_f="26089" txt_i="13610" txt_f="13612">33</offsets></xref><offsets xml_i="26096" xml_f="26184" txt_i="13612" txt_f="13700">) show advantage of mitoxantrone use in reducing disability of secondary progressive MS.</offsets></p><p><offsets xml_i="26191" xml_f="26957" txt_i="13701" txt_f="14461">Our study showed that the mean EDSS in the group treated with mitoxantrone decreased from 5.17 to 4.64 after the treatment and in the group treated with mitoxantrone and methylprednisolone, this decrement was from 5.4 to 4.6. Both these decrements were significant (P &lt; 0.05), but the difference between the groups was not significant (P &gt; 0.05). EDSS increased in both groups during six months after drug administration completion, but the difference was not significant. Although its efficacy in SPMS is not proven, the importance of glucocorticosteroids in treatment of progressive MS is still undisputed. The results of different trials suggest that glucocorticosteroids may improve inflammation, but at later stages degeneration can hardly be influenced (</offsets><xref rid="A30618R9" ref-type="bibr"><offsets xml_i="26994" xml_f="26995" txt_i="14461" txt_f="14462">9</offsets></xref><offsets xml_i="27002" xml_f="27005" txt_i="14462" txt_f="14465">). </offsets><xref ref-type="table" rid="tbl33195"><offsets xml_i="27043" xml_f="27050" txt_i="14465" txt_f="14472">Table 4</offsets></xref><offsets xml_i="27057" xml_f="27316" txt_i="14472" txt_f="14731"> shows paradoxes in efficacy of glucocorticosteroids therapy in MS. The strong points of our study were highly cooperative patients, study design and low missing values. The weak points were lack of MRI with contrast (due to high cost) and follow-up duration.</offsets></p><table-wrap id="tbl33195" orientation="portrait" position="float"><label><offsets xml_i="27393" xml_f="27401" txt_i="14732" txt_f="14740">Table 4.</offsets></label><caption><title><offsets xml_i="27425" xml_f="27489" txt_i="14740" txt_f="14804"> Studies Regarding Corticosteroids Therapy in Multiple Sclerosis</offsets></title></caption><table frame="hsides" rules="groups"><thead><tr><th style="text-align: left;" rowspan="1" colspan="1"><offsets xml_i="27609" xml_f="27614" txt_i="14805" txt_f="14810">Study</offsets></th><th rowspan="1" colspan="1"><offsets xml_i="27647" xml_f="27657" txt_i="14810" txt_f="14820">Type of MS</offsets></th><th rowspan="1" colspan="1"><offsets xml_i="27690" xml_f="27707" txt_i="14820" txt_f="14837">Root of Treatment</offsets></th><th rowspan="1" colspan="1"><offsets xml_i="27740" xml_f="27746" txt_i="14837" txt_f="14843">Result</offsets></th></tr></thead><tbody><tr style="vertical-align: top;"><td rowspan="1" colspan="1"><offsets xml_i="27832" xml_f="27833" txt_i="14843" txt_f="14844">
</offsets><bold><offsets xml_i="27839" xml_f="27866" txt_i="14844" txt_f="14871">Bergamaschi et al. (1993) (</offsets></bold><xref rid="A30618R18" ref-type="bibr"><offsets xml_i="27911" xml_f="27913" txt_i="14871" txt_f="14873">18</offsets></xref><bold><offsets xml_i="27926" xml_f="27928" txt_i="14873" txt_f="14875">) </offsets></bold><offsets xml_i="27935" xml_f="27936" txt_i="14875" txt_f="14876">
</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="27997" xml_f="28000" txt_i="14877" txt_f="14880">PMS</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="28061" xml_f="28090" txt_i="14881" txt_f="14910">1000 mg IVMP daily for 6 days</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="28151" xml_f="28304" txt_i="14911" txt_f="15064">1- Delay in progression in progressive MS in 18 patients, whereas a worsening was present in 13 patients. 2- Disability was not affected by repeated IVMP</offsets></td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1"><offsets xml_i="28375" xml_f="28376" txt_i="15065" txt_f="15066">
</offsets><bold><offsets xml_i="28382" xml_f="28405" txt_i="15066" txt_f="15089">Frequin et al. (1994) (</offsets></bold><xref rid="A30618R19" ref-type="bibr"><offsets xml_i="28450" xml_f="28452" txt_i="15089" txt_f="15091">19</offsets></xref><bold><offsets xml_i="28465" xml_f="28466" txt_i="15091" txt_f="15092">)</offsets></bold><offsets xml_i="28473" xml_f="28474" txt_i="15092" txt_f="15093">
</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="28535" xml_f="28548" txt_i="15094" txt_f="15107">RRMS and RPMS</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="28609" xml_f="28735" txt_i="15108" txt_f="15234">1000 mg IVMP for 10 days, the application was repeated depending on sustaining deterioration on repeated clinical examinations</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="28796" xml_f="28825" txt_i="15235" txt_f="15264">Reduction in the relapse rate</offsets></td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1"><offsets xml_i="28896" xml_f="28897" txt_i="15265" txt_f="15266">
</offsets><bold><offsets xml_i="28903" xml_f="28926" txt_i="15266" txt_f="15289">Goodkin et al. (1998) (</offsets></bold><xref rid="A30618R20" ref-type="bibr"><offsets xml_i="28971" xml_f="28973" txt_i="15289" txt_f="15291">20</offsets></xref><bold><offsets xml_i="28986" xml_f="28987" txt_i="15291" txt_f="15292">)</offsets></bold><offsets xml_i="28994" xml_f="28995" txt_i="15292" txt_f="15293">
</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="29056" xml_f="29060" txt_i="15294" txt_f="15298">SPMS</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="29121" xml_f="29155" txt_i="15299" txt_f="15333">500 mg IVMP bimonthly over 2 years</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="29216" xml_f="29261" txt_i="15334" txt_f="15379">Delay of onset on ongoing disease progression</offsets></td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1"><offsets xml_i="29332" xml_f="29333" txt_i="15380" txt_f="15381">
</offsets><bold><offsets xml_i="29339" xml_f="29364" txt_i="15381" txt_f="15406">Zivadinov et al. (2001) (</offsets></bold><xref rid="A30618R34" ref-type="bibr"><offsets xml_i="29409" xml_f="29411" txt_i="15406" txt_f="15408">34</offsets></xref><bold><offsets xml_i="29424" xml_f="29425" txt_i="15408" txt_f="15409">)</offsets></bold><offsets xml_i="29432" xml_f="29433" txt_i="15409" txt_f="15410">
</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="29494" xml_f="29498" txt_i="15411" txt_f="15415">RRMS</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="29559" xml_f="29660" txt_i="15416" txt_f="15517">1000 mg IVMP was given every 4 months for 3 years and then every 6 months for the subsequent 2 years.</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="29721" xml_f="29824" txt_i="15518" txt_f="15621">Slows development of T1 black holes, prevents or delays whole-brain atrophy and disability progression.</offsets></td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1"><offsets xml_i="29895" xml_f="29896" txt_i="15622" txt_f="15623">
</offsets><bold><offsets xml_i="29902" xml_f="29923" txt_i="15623" txt_f="15644">Pirko et al. (2004) (</offsets></bold><xref rid="A30618R35" ref-type="bibr"><offsets xml_i="29968" xml_f="29970" txt_i="15644" txt_f="15646">35</offsets></xref><bold><offsets xml_i="29983" xml_f="29984" txt_i="15646" txt_f="15647">)</offsets></bold><offsets xml_i="29991" xml_f="29992" txt_i="15647" txt_f="15648">
</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="30053" xml_f="30065" txt_i="15649" txt_f="15661">PPMS or SPMS</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="30126" xml_f="30152" txt_i="15662" txt_f="15688">Pulses of IVMP every month</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="30213" xml_f="30328" txt_i="15689" txt_f="15804">1- Improvement in fatigue, spasticity and motor strength. 2- Acute exacerbations were occurred in 9 of 10 patients.</offsets></td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1"><offsets xml_i="30399" xml_f="30400" txt_i="15805" txt_f="15806">
</offsets><bold><offsets xml_i="30406" xml_f="30429" txt_i="15806" txt_f="15829">Zingler et al. (2005) (</offsets></bold><xref rid="A30618R26" ref-type="bibr"><offsets xml_i="30474" xml_f="30476" txt_i="15829" txt_f="15831">26</offsets></xref><bold><offsets xml_i="30489" xml_f="30490" txt_i="15831" txt_f="15832">)</offsets></bold><offsets xml_i="30497" xml_f="30498" txt_i="15832" txt_f="15833">
</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="30559" xml_f="30572" txt_i="15834" txt_f="15847">PPMS and SPMS</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="30633" xml_f="30779" txt_i="15848" txt_f="15994">10 cycles of combined mitox and MP. The intervals between the individual cycles were systematically prolonged from 3 months initially to 12 months</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="30840" xml_f="30948" txt_i="15995" txt_f="16103">Mitox. combined with MP beneficially reduces the progression of disability in patients with PP-MS and SP-MS.</offsets></td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1"><offsets xml_i="31019" xml_f="31020" txt_i="16104" txt_f="16105">
</offsets><bold><offsets xml_i="31026" xml_f="31048" txt_i="16105" txt_f="16127">Araujo et al. (2008) (</offsets></bold><xref rid="A30618R36" ref-type="bibr"><offsets xml_i="31093" xml_f="31095" txt_i="16127" txt_f="16129">36</offsets></xref><bold><offsets xml_i="31108" xml_f="31109" txt_i="16129" txt_f="16130">)</offsets></bold><offsets xml_i="31116" xml_f="31117" txt_i="16130" txt_f="16131">
</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="31178" xml_f="31182" txt_i="16132" txt_f="16136">PPMS</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="31243" xml_f="31274" txt_i="16137" txt_f="16168">Periodic use of IVMP (30 mg/kg)</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="31335" xml_f="31382" txt_i="16169" txt_f="16216">Decreased EDSS and postponed clinical worsening</offsets></td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1"><offsets xml_i="31453" xml_f="31454" txt_i="16217" txt_f="16218">
</offsets><bold><offsets xml_i="31460" xml_f="31481" txt_i="16218" txt_f="16239">Cohen et al. (2009) (</offsets></bold><xref rid="A30618R11" ref-type="bibr"><offsets xml_i="31526" xml_f="31528" txt_i="16239" txt_f="16241">11</offsets></xref><bold><offsets xml_i="31541" xml_f="31542" txt_i="16241" txt_f="16242">)</offsets></bold><offsets xml_i="31549" xml_f="31550" txt_i="16242" txt_f="16243">
</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="31611" xml_f="31615" txt_i="16244" txt_f="16248">RRMS</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="31676" xml_f="31796" txt_i="16249" txt_f="16369">Adding low-dose oral methotrexate(20 mg weekly) or every other month IVMP (1000 mg/day for 3 days) to interferon beta-1a</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="31857" xml_f="31953" txt_i="16370" txt_f="16466">No benefit ( The primary endpoint was new or enlarged T2 lesion number at month 12 vs. baseline)</offsets></td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1"><offsets xml_i="32024" xml_f="32025" txt_i="16467" txt_f="16468">
</offsets><bold><offsets xml_i="32031" xml_f="32055" txt_i="16468" txt_f="16492">Sorensen et al. (2009) (</offsets></bold><xref rid="A30618R37" ref-type="bibr"><offsets xml_i="32100" xml_f="32102" txt_i="16492" txt_f="16494">37</offsets></xref><bold><offsets xml_i="32115" xml_f="32116" txt_i="16494" txt_f="16495">)</offsets></bold><offsets xml_i="32123" xml_f="32124" txt_i="16495" txt_f="16496">
</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="32185" xml_f="32189" txt_i="16497" txt_f="16501">RRMS</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="32250" xml_f="32343" txt_i="16502" txt_f="16595">Oral MP given in pulses every 4 weeks as an add-on therapy to subcutaneous interferon beta-1a</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="32404" xml_f="32429" txt_i="16596" txt_f="16621">Reduction in relapse rate</offsets></td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1"><offsets xml_i="32500" xml_f="32501" txt_i="16622" txt_f="16623">
</offsets><bold><offsets xml_i="32507" xml_f="32531" txt_i="16623" txt_f="16647">Ravnborg et al. (2010) (</offsets></bold><xref rid="A30618R38" ref-type="bibr"><offsets xml_i="32576" xml_f="32578" txt_i="16647" txt_f="16649">38</offsets></xref><bold><offsets xml_i="32591" xml_f="32592" txt_i="16649" txt_f="16650">)</offsets></bold><offsets xml_i="32599" xml_f="32600" txt_i="16650" txt_f="16651">
</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="32661" xml_f="32665" txt_i="16652" txt_f="16656">RRMS</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="32726" xml_f="32787" txt_i="16657" txt_f="16718">Monthly pulses of IVMP in combination with interferon beta-1a</offsets></td><td style="text-align: center;" rowspan="1" colspan="1"><offsets xml_i="32848" xml_f="32883" txt_i="16719" txt_f="16754">No effect on disability progression</offsets></td></tr></tbody></table></table-wrap><p><offsets xml_i="32925" xml_f="33486" txt_i="16755" txt_f="17316">This study concluded that there were no significant differences in the clinical and radiologic results and long-term prognosis of patients with SPMS treated with mitoxantrone plus methylprednisolone versus mitoxantrone alone. Corticosteroid pulse therapy in SPMS was effective in inflammatory process, but could not postpone or decline the neurodegenerative process and besides the imposing adverse effects could not result in significant improvement in EDSS and MRI plaques number in long term. More studies should be performed for drawing certain conclusions.</offsets></p></sec></body><back><ack><p>We thank Shahid Sadoughi University of Medical Sciences, participants, coordinators and data reviewers who assisted in this study.</p></ack><fn-group><fn id="afn43698" fn-type="other"><p><bold>Authorsâ Contributions:</bold>Abolghasem Rahimdel, Ahmad Zeinal and Ali Mellat participated in the study design, data analysis, literature review, preparation and editing the manuscript.</p></fn><fn id="afn43699" fn-type="supported-by"><p><bold>Funding/Support:</bold>This study was supported by Shahid Sadoughi University of Medical Sciences.</p></fn></fn-group><ref-list><title>References</title><ref id="A30618R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whetten-Goldstein</surname><given-names>K</given-names></name><name><surname>Sloan</surname><given-names>FA</given-names></name><name><surname>Goldstein</surname><given-names>LB</given-names></name><name><surname>Kulas</surname><given-names>ED</given-names></name></person-group><article-title>A comprehensive assessment of the cost of multiple sclerosis in the United States.</article-title><source>Mult Scler.</source><year>1998</year><volume>4</volume><issue>5</issue><fpage>419</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">9839302</pub-id></element-citation></ref><ref id="A30618R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brex</surname><given-names>PA</given-names></name><name><surname>Ciccarelli</surname><given-names>O</given-names></name><name><surname>O'Riordan</surname><given-names>JI</given-names></name><name><surname>Sailer</surname><given-names>M</given-names></name><name><surname>Thompson</surname><given-names>AJ</given-names></name><name><surname>Miller</surname><given-names>DH</given-names></name></person-group><article-title>A longitudinal study of abnormalities on MRI and disability from multiple sclerosis.</article-title><source>N Engl J Med.</source><year>2002</year><volume>346</volume><issue>3</issue><fpage>158</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa011341</pub-id><pub-id pub-id-type="pmid">11796849</pub-id></element-citation></ref><ref id="A30618R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lublin</surname><given-names>FD</given-names></name><name><surname>Reingold</surname><given-names>SC</given-names></name></person-group><article-title>Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.</article-title><source>Neurology.</source><year>1996</year><volume>46</volume><issue>4</issue><fpage>907</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">8780061</pub-id></element-citation></ref><ref id="A30618R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinshenker</surname><given-names>BG</given-names></name></person-group><article-title>The natural history of multiple sclerosis: update 1998.</article-title><source>Semin Neurol.</source><year>1998</year><volume>18</volume><issue>3</issue><fpage>301</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1055/s-2008-1040881</pub-id><pub-id pub-id-type="pmid">9817534</pub-id></element-citation></ref><ref id="A30618R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kesselring</surname><given-names>J</given-names></name></person-group><article-title>Forum: Rehabilitation in MS Is Effective.</article-title><source>Int MS J.</source><year>2001</year><volume>8</volume><issue>2</issue><fpage>68</fpage><lpage>71</lpage></element-citation></ref><ref id="A30618R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frischer</surname><given-names>JM</given-names></name><name><surname>Bramow</surname><given-names>S</given-names></name><name><surname>Dal-Bianco</surname><given-names>A</given-names></name><name><surname>Lucchinetti</surname><given-names>CF</given-names></name><name><surname>Rauschka</surname><given-names>H</given-names></name><name><surname>Schmidbauer</surname><given-names>M</given-names></name><etal>et al.</etal></person-group><article-title>The relation between inflammation and neurodegeneration in multiple sclerosis brains.</article-title><source>Brain.</source><year>2009</year><volume>132</volume><issue>Pt 5</issue><fpage>1175</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1093/brain/awp070</pub-id><pub-id pub-id-type="pmid">19339255</pub-id></element-citation></ref><ref id="A30618R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luessi</surname><given-names>F</given-names></name><name><surname>Siffrin</surname><given-names>V</given-names></name><name><surname>Zipp</surname><given-names>F</given-names></name></person-group><article-title>Neurodegeneration in multiple sclerosis: novel treatment strategies.</article-title><source>Expert Rev Neurother.</source><year>2012</year><volume>12</volume><issue>9</issue><fpage>1061</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1586/ern.12.59</pub-id><pub-id pub-id-type="pmid">23039386</pub-id></element-citation></ref><ref id="A30618R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lassmann</surname><given-names>H</given-names></name></person-group><article-title>Cortical lesions in multiple sclerosis: inflammation versus neurodegeneration.</article-title><source>Brain.</source><year>2012</year><volume>135</volume><issue>Pt 10</issue><fpage>2904</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1093/brain/aws260</pub-id><pub-id pub-id-type="pmid">23065786</pub-id></element-citation></ref><ref id="A30618R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rommer</surname><given-names>PS</given-names></name><name><surname>Stuve</surname><given-names>O</given-names></name></person-group><article-title>Management of secondary progressive multiple sclerosis: prophylactic treatment-past, present, and future aspects.</article-title><source>Curr Treat Options Neurol.</source><year>2013</year><volume>15</volume><issue>3</issue><fpage>241</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1007/s11940-013-0233-x</pub-id><pub-id pub-id-type="pmid">23609781</pub-id></element-citation></ref><ref id="A30618R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rieckmann</surname><given-names>P</given-names></name><name><surname>Toyka</surname><given-names>KV</given-names></name></person-group><article-title>Escalating immunotherapy of multiple sclerosis.Austrian-German- Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG].</article-title><source>Eur Neurol.</source><year>1999</year><volume>42</volume><issue>3</issue><fpage>121</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1159/000008084</pub-id><pub-id pub-id-type="pmid">10529535</pub-id></element-citation></ref><ref id="A30618R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>BA</given-names></name><name><surname>Mikol</surname><given-names>DD</given-names></name></person-group><article-title>Mitoxantrone treatment of multiple sclerosis: safety considerations.</article-title><source>Neurology.</source><year>2004</year><volume>63</volume><issue>12 Suppl 6</issue><fpage>S28</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">15623667</pub-id></element-citation></ref><ref id="A30618R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vicari</surname><given-names>AM</given-names></name><name><surname>Ciceri</surname><given-names>F</given-names></name><name><surname>Folli</surname><given-names>F</given-names></name><name><surname>Lanzi</surname><given-names>R</given-names></name><name><surname>Colombo</surname><given-names>B</given-names></name><name><surname>Comi</surname><given-names>G</given-names></name><etal>et al.</etal></person-group><article-title>Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis.</article-title><source>Leukemia.</source><year>1998</year><volume>12</volume><issue>3</issue><fpage>441</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">9529141</pub-id></element-citation></ref><ref id="A30618R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Posner</surname><given-names>LE</given-names></name><name><surname>Dukart</surname><given-names>G</given-names></name><name><surname>Goldberg</surname><given-names>J</given-names></name><name><surname>Bernstein</surname><given-names>T</given-names></name><name><surname>Cartwright</surname><given-names>K</given-names></name></person-group><article-title>Mitoxantrone: an overview of safety and toxicity.</article-title><source>Invest New Drugs.</source><year>1985</year><volume>3</volume><issue>2</issue><fpage>123</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">3894276</pub-id></element-citation></ref><ref id="A30618R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>LJ</given-names></name><name><surname>Figgitt</surname><given-names>DP</given-names></name></person-group><article-title>Mitoxantrone: a review of its use in multiple sclerosis.</article-title><source>CNS Drugs.</source><year>2004</year><volume>18</volume><issue>6</issue><fpage>379</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">15089110</pub-id></element-citation></ref><ref id="A30618R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartung</surname><given-names>HP</given-names></name><name><surname>Gonsette</surname><given-names>R</given-names></name><name><surname>Konig</surname><given-names>N</given-names></name><name><surname>Kwiecinski</surname><given-names>H</given-names></name><name><surname>Guseo</surname><given-names>A</given-names></name><name><surname>Morrissey</surname><given-names>SP</given-names></name><etal>et al.</etal></person-group><article-title>Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.</article-title><source>Lancet.</source><year>2002</year><volume>360</volume><issue>9350</issue><fpage>2018</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(02)12023-X</pub-id><pub-id pub-id-type="pmid">12504397</pub-id></element-citation></ref><ref id="A30618R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noseworthy</surname><given-names>JH</given-names></name><name><surname>Lucchinetti</surname><given-names>C</given-names></name><name><surname>Rodriguez</surname><given-names>M</given-names></name><name><surname>Weinshenker</surname><given-names>BG</given-names></name></person-group><article-title>Multiple sclerosis.</article-title><source>N Engl J Med.</source><year>2000</year><volume>343</volume><issue>13</issue><fpage>938</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1056/NEJM200009283431307</pub-id><pub-id pub-id-type="pmid">11006371</pub-id></element-citation></ref><ref id="A30618R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>WI</given-names></name><name><surname>Compston</surname><given-names>A</given-names></name><name><surname>Edan</surname><given-names>G</given-names></name><name><surname>Goodkin</surname><given-names>D</given-names></name><name><surname>Hartung</surname><given-names>HP</given-names></name><name><surname>Lublin</surname><given-names>FD</given-names></name><etal>et al.</etal></person-group><article-title>Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.</article-title><source>Ann Neurol.</source><year>2001</year><volume>50</volume><issue>1</issue><fpage>121</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11456302</pub-id></element-citation></ref><ref id="A30618R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergamaschi</surname><given-names>R</given-names></name><name><surname>Versino</surname><given-names>M</given-names></name><name><surname>Raiola</surname><given-names>E</given-names></name><name><surname>Citterio</surname><given-names>A</given-names></name><name><surname>Cosi</surname><given-names>V</given-names></name></person-group><article-title>High-dose methylprednisolone infusions in relapsing and in chronic progressive multiple sclerosis patients. One year follow-up.</article-title><source>Acta Neurol (Napoli).</source><year>1993</year><volume>15</volume><issue>1</issue><fpage>33</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">8456594</pub-id></element-citation></ref><ref id="A30618R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frequin</surname><given-names>ST</given-names></name><name><surname>Lamers</surname><given-names>KJ</given-names></name><name><surname>Barkhof</surname><given-names>F</given-names></name><name><surname>Borm</surname><given-names>GF</given-names></name><name><surname>Hommes</surname><given-names>OR</given-names></name></person-group><article-title>Follow-up study of MS patients treated with high-dose intravenous methylprednisolone.</article-title><source>Acta Neurol Scand.</source><year>1994</year><volume>90</volume><issue>2</issue><fpage>105</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">7801735</pub-id></element-citation></ref><ref id="A30618R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodkin</surname><given-names>DE</given-names></name><name><surname>Kinkel</surname><given-names>RP</given-names></name><name><surname>Weinstock-Guttman</surname><given-names>B</given-names></name><name><surname>VanderBrug-Medendorp</surname><given-names>S</given-names></name><name><surname>Secic</surname><given-names>M</given-names></name><name><surname>Gogol</surname><given-names>D</given-names></name><etal>et al.</etal></person-group><article-title>A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis.</article-title><source>Neurology.</source><year>1998</year><volume>51</volume><issue>1</issue><fpage>239</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">9674809</pub-id></element-citation></ref><ref id="A30618R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chau</surname><given-names>SY</given-names></name><name><surname>Mok</surname><given-names>CC</given-names></name></person-group><article-title>Factors predictive of corticosteroid psychosis in patients with systemic lupus erythematosus.</article-title><source>Neurology.</source><year>2003</year><volume>61</volume><issue>1</issue><fpage>104</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12847167</pub-id></element-citation></ref><ref id="A30618R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stadler</surname><given-names>C</given-names></name><name><surname>Vuadens</surname><given-names>P</given-names></name><name><surname>Dewarrat</surname><given-names>A</given-names></name><name><surname>Janzer</surname><given-names>R</given-names></name><name><surname>Uske</surname><given-names>A</given-names></name><name><surname>Bogousslavsky</surname><given-names>J</given-names></name></person-group><article-title>[Cerebral venous thrombosis after lumbar puncture and intravenous steroids in two patients with multiple sclerosis].</article-title><source>Rev Neurol (Paris).</source><year>2000</year><volume>156</volume><issue>2</issue><fpage>155</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10743014</pub-id></element-citation></ref><ref id="A30618R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stolz</surname><given-names>E</given-names></name><name><surname>Klotzsch</surname><given-names>C</given-names></name><name><surname>Schlachetzki</surname><given-names>F</given-names></name><name><surname>Rahimi</surname><given-names>A</given-names></name></person-group><article-title>High-dose corticosteroid treatment is associated with an increased risk of developing cerebral venous thrombosis.</article-title><source>Eur Neurol.</source><year>2003</year><volume>49</volume><issue>4</issue><fpage>247</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1159/000070197</pub-id><pub-id pub-id-type="pmid">12736545</pub-id></element-citation></ref><ref id="A30618R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brusaferri</surname><given-names>F</given-names></name><name><surname>Candelise</surname><given-names>L</given-names></name></person-group><article-title>Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials.</article-title><source>J Neurol.</source><year>2000</year><volume>247</volume><issue>6</issue><fpage>435</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">10929272</pub-id></element-citation></ref><ref id="A30618R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filippini</surname><given-names>G</given-names></name><name><surname>Brusaferri</surname><given-names>F</given-names></name><name><surname>Sibley</surname><given-names>WA</given-names></name><name><surname>Citterio</surname><given-names>A</given-names></name><name><surname>Ciucci</surname><given-names>G</given-names></name><name><surname>Midgard</surname><given-names>R</given-names></name><etal>et al.</etal></person-group><article-title>Corticosteroids or ACTH for acute exacerbations in multiple sclerosis.</article-title><source>Cochrane Database Syst Rev.</source><year>2000</year><issue>4</issue><fpage>CD001331</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD001331</pub-id><pub-id pub-id-type="pmid">11034713</pub-id></element-citation></ref><ref id="A30618R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zingler</surname><given-names>VC</given-names></name><name><surname>Strupp</surname><given-names>M</given-names></name><name><surname>Jahn</surname><given-names>K</given-names></name><name><surname>Gross</surname><given-names>A</given-names></name><name><surname>Hohlfeld</surname><given-names>R</given-names></name><name><surname>Brandt</surname><given-names>T</given-names></name></person-group><article-title>[The effect of combined mitoxantrone and methylprednisolone therapy in primary and secondary progressive multiple sclerosis. An applied study in 65 patients].</article-title><source>Nervenarzt.</source><year>2005</year><volume>76</volume><issue>6</issue><fpage>740</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1007/s00115-005-1885-x</pub-id><pub-id pub-id-type="pmid">15803287</pub-id></element-citation></ref><ref id="A30618R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McFarland</surname><given-names>HF</given-names></name><name><surname>Frank</surname><given-names>JA</given-names></name><name><surname>Albert</surname><given-names>PS</given-names></name><name><surname>Smith</surname><given-names>ME</given-names></name><name><surname>Martin</surname><given-names>R</given-names></name><name><surname>Harris</surname><given-names>JO</given-names></name><etal>et al.</etal></person-group><article-title>Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis.</article-title><source>Ann Neurol.</source><year>1992</year><volume>32</volume><issue>6</issue><fpage>758</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1002/ana.410320609</pub-id><pub-id pub-id-type="pmid">1471866</pub-id></element-citation></ref><ref id="A30618R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>DH</given-names></name><name><surname>Barkhof</surname><given-names>F</given-names></name><name><surname>Berry</surname><given-names>I</given-names></name><name><surname>Kappos</surname><given-names>L</given-names></name><name><surname>Scotti</surname><given-names>G</given-names></name><name><surname>Thompson</surname><given-names>AJ</given-names></name></person-group><article-title>Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines.</article-title><source>J Neurol Neurosurg Psychiatry.</source><year>1991</year><volume>54</volume><issue>8</issue><fpage>683</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">1940938</pub-id></element-citation></ref><ref id="A30618R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edan</surname><given-names>G</given-names></name><name><surname>Miller</surname><given-names>D</given-names></name><name><surname>Clanet</surname><given-names>M</given-names></name><name><surname>Confavreux</surname><given-names>C</given-names></name><name><surname>Lyon-Caen</surname><given-names>O</given-names></name><name><surname>Lubetzki</surname><given-names>C</given-names></name><etal>et al.</etal></person-group><article-title>Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.</article-title><source>J Neurol Neurosurg Psychiatry.</source><year>1997</year><volume>62</volume><issue>2</issue><fpage>112</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9048709</pub-id></element-citation></ref><ref id="A30618R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Page</surname><given-names>E</given-names></name><name><surname>Leray</surname><given-names>E</given-names></name><name><surname>Edan</surname><given-names>G</given-names></name><name><surname>French Mitoxantrone Safety</surname><given-names>G</given-names></name></person-group><article-title>Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.</article-title><source>Mult Scler.</source><year>2011</year><volume>17</volume><issue>7</issue><fpage>867</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1177/1352458511398371</pub-id><pub-id pub-id-type="pmid">21325016</pub-id></element-citation></ref><ref id="A30618R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Page</surname><given-names>E</given-names></name><name><surname>Leray</surname><given-names>E</given-names></name><name><surname>Taurin</surname><given-names>G</given-names></name><name><surname>Coustans</surname><given-names>M</given-names></name><name><surname>Chaperon</surname><given-names>J</given-names></name><name><surname>Edan</surname><given-names>G</given-names></name></person-group><article-title>[Mitoxantrone as induction therapy in aggressive relapsing remitting multiple sclerosis: a descriptive analysis of 100 consecutive patients].</article-title><source>Rev Neurol (Paris).</source><year>2006</year><volume>162</volume><issue>2</issue><fpage>185</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">16518258</pub-id></element-citation></ref><ref id="A30618R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamzehloo</surname><given-names>A</given-names></name><name><surname>Etemadifar</surname><given-names>M</given-names></name></person-group><article-title>Mitoxantrone reduced disability in Iranian patients with multiple sclerosis.</article-title><source>Arch Iran Med.</source><year>2007</year><volume>10</volume><issue>1</issue><fpage>59</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">17198456</pub-id></element-citation></ref><ref id="A30618R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Wyngaert</surname><given-names>FA</given-names></name><name><surname>Beguin</surname><given-names>C</given-names></name><name><surname>D'Hooghe</surname><given-names>MB</given-names></name><name><surname>Dooms</surname><given-names>G</given-names></name><name><surname>Lissoir</surname><given-names>F</given-names></name><name><surname>Carton</surname><given-names>H</given-names></name><etal>et al.</etal></person-group><article-title>A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.</article-title><source>Acta Neurol Belg.</source><year>2001</year><volume>101</volume><issue>4</issue><fpage>210</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">11851027</pub-id></element-citation></ref><ref id="A30618R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zivadinov</surname><given-names>R</given-names></name><name><surname>Rudick</surname><given-names>RA</given-names></name><name><surname>De Masi</surname><given-names>R</given-names></name><name><surname>Nasuelli</surname><given-names>D</given-names></name><name><surname>Ukmar</surname><given-names>M</given-names></name><name><surname>Pozzi-Mucelli</surname><given-names>RS</given-names></name><etal>et al.</etal></person-group><article-title>Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.</article-title><source>Neurology.</source><year>2001</year><volume>57</volume><issue>7</issue><fpage>1239</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">11591843</pub-id></element-citation></ref><ref id="A30618R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pirko</surname><given-names>I</given-names></name><name><surname>Rodriguez</surname><given-names>M</given-names></name></person-group><article-title>Pulsed intravenous methylprednisolone therapy in progressive multiple sclerosis: need for a controlled trial.</article-title><source>Arch Neurol.</source><year>2004</year><volume>61</volume><issue>7</issue><fpage>1148</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1001/archneur.61.7.1148</pub-id><pub-id pub-id-type="pmid">15262754</pub-id></element-citation></ref><ref id="A30618R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Araujo</surname><given-names>EA</given-names></name><name><surname>Freitas</surname><given-names>MR</given-names></name></person-group><article-title>Benefit with methylprednisolone in continuous pulsetherapy in progressive primary form of multiple sclerosis: study of 11 cases in 11 years.</article-title><source>Arq Neuropsiquiatr.</source><year>2008</year><volume>66</volume><issue>2B</issue><fpage>350</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">18641870</pub-id></element-citation></ref><ref id="A30618R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorensen</surname><given-names>PS</given-names></name><name><surname>Mellgren</surname><given-names>SI</given-names></name><name><surname>Svenningsson</surname><given-names>A</given-names></name><name><surname>Elovaara</surname><given-names>I</given-names></name><name><surname>Frederiksen</surname><given-names>JL</given-names></name><name><surname>Beiske</surname><given-names>AG</given-names></name><etal>et al.</etal></person-group><article-title>NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.</article-title><source>Lancet Neurol.</source><year>2009</year><volume>8</volume><issue>6</issue><fpage>519</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/s1474-4422(09)70085-7</pub-id><pub-id pub-id-type="pmid">19409854</pub-id></element-citation></ref><ref id="A30618R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravnborg</surname><given-names>M</given-names></name><name><surname>SÃ¸rensen</surname><given-names>PS</given-names></name><name><surname>Andersson</surname><given-names>M</given-names></name><name><surname>Celius</surname><given-names>EG</given-names></name><name><surname>Jongen</surname><given-names>PJ</given-names></name><name><surname>Elovaara</surname><given-names>I</given-names></name><etal>et al.</etal></person-group><article-title>Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.</article-title><source>Lancet Neurol.</source><year>2010</year><volume>9</volume><issue>7</issue><fpage>672</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/s1474-4422(10)70132-0</pub-id><pub-id pub-id-type="pmid">20542736</pub-id></element-citation></ref></ref-list></back></article>